News
Apretude is a long-acting injectable medication used for HIV pre-exposure prophylaxis (PrEP). Planned Parenthood will offer ...
Scientific research has gifted us with a range of evidence-based options to protect ourselves from getting infected with HIV.
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...
Is the cost of research aimed at curing HIV worth it, when HIV can be effectively managed and prevented by existing drugs?
3d
Good Good Good on MSNHere's everything you need to know about lenacapavir, the newly approved HIV-prevention injectionThe United States Food and Drug Administration has approved lenacapavir, an injectable drug that offers long-lasting ...
The Los Angeles County Department of Public Health received notice from the U.S. Centers for Disease Control and Prevention ...
The COVID-19 pandemic paused many HIV prevention efforts, which helped fuel last year's rise in new infections. President ...
Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be HIV-negative to get it.
State's Health Outreach and Prevention program will end June 30 after federal funding cuts to HIV outreach and prevention ...
Clinical trials showed 99.9% of participants who received the drug, called Yeztugo from company Gilead Sciences, remained ...
June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.
A drug with the potential to drastically curb the HIV epidemic just cleared its first regulatory hurdle. On Wednesday, the Food and Drug Administration approved lenacapavir for the prevention of HIV.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results